David S. Warren

Array ( [id] => 15178925 [patent_doc_number] => 20190360054 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-11-28 [patent_title] => METHOD FOR DIAGNOSIS OF METASTATIC CANCER OR TAXANE-BASED DRUG-RESISTANT CANCER BY USING LMCD1 PROTEIN AND GENE CODING THEREFOR [patent_app_type] => utility [patent_app_number] => 16/413014 [patent_app_country] => US [patent_app_date] => 2019-05-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 10639 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 90 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16413014 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16688773 [patent_doc_number] => 20210071249 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-03-11 [patent_title] => DIAGNOSTIC METHOD AND THERAPY [patent_app_type] => utility [patent_app_number] => 17/051930 [patent_app_country] => US [patent_app_date] => 2019-05-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 7459 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -8 [patent_words_short_claim] => 24 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17051930 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17815424 [patent_doc_number] => 11421023 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2022-08-23 [patent_title] => Anti-GP73 monoclonal antibodies and methods of obtaining the same [patent_app_type] => utility [patent_app_number] => 16/387282 [patent_app_country] => US [patent_app_date] => 2019-04-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 21 [patent_figures_cnt] => 27 [patent_no_of_words] => 60624 [patent_no_of_claims] => 5 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 292 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16387282 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15038703 [patent_doc_number] => 20190330356 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-10-31 [patent_title] => TREATMENT OF CANCER USING HUMANIZED ANTI-EGFRVIII CHIMERIC ANTIGEN RECEPTOR [patent_app_type] => utility [patent_app_number] => 16/382402 [patent_app_country] => US [patent_app_date] => 2019-04-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 51821 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -33 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16382402 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14932951 [patent_doc_number] => 20190302113 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-10-03 [patent_title] => MATERIAL AND METHODS FOR DIAGNOSING AND TREATING KAWASAKI DISEASE AND KLS [patent_app_type] => utility [patent_app_number] => 16/375283 [patent_app_country] => US [patent_app_date] => 2019-04-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 10386 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 142 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16375283 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14833411 [patent_doc_number] => 20190275106 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-09-12 [patent_title] => Anti-Angiogenic Gene Therapy Kit [patent_app_type] => utility [patent_app_number] => 16/364284 [patent_app_country] => US [patent_app_date] => 2019-03-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 4411 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -9 [patent_words_short_claim] => 89 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16364284 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14929963 [patent_doc_number] => 20190300619 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-10-03 [patent_title] => GITR AGONISTS, AND METHODS OF USE THEREOF [patent_app_type] => utility [patent_app_number] => 16/358522 [patent_app_country] => US [patent_app_date] => 2019-03-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 17291 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -15 [patent_words_short_claim] => 19 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16358522 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14716183 [patent_doc_number] => 20190249155 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-08-15 [patent_title] => FUSION PROTEINS COMPRISING ENZYME REPLACEMENT THERAPY ENZYMES [patent_app_type] => utility [patent_app_number] => 16/355339 [patent_app_country] => US [patent_app_date] => 2019-03-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 51575 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -28 [patent_words_short_claim] => 85 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16355339 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16582844 [patent_doc_number] => 20210017246 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-01-21 [patent_title] => IL-13 RECEPTOR ALPHA 2 TARGETED, ZETAKINE DIRECTED T CELL IMMUNOTHERAPY [patent_app_type] => utility [patent_app_number] => 16/979475 [patent_app_country] => US [patent_app_date] => 2019-03-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 12443 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => 0 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16979475 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14687595 [patent_doc_number] => 20190242912 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-08-08 [patent_title] => COMPOSITION AND METHOD FOR MEASURING THALLIUM INFLUX AND EFFLUX [patent_app_type] => utility [patent_app_number] => 16/298810 [patent_app_country] => US [patent_app_date] => 2019-03-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 11213 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -15 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16298810 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15713301 [patent_doc_number] => 20200103416 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-04-02 [patent_title] => SNX9 as a novel biomarker for chronic inflammation and associated immunosuppresion and a new regulator of T cell receptor expression and function [patent_app_type] => utility [patent_app_number] => 16/501210 [patent_app_country] => US [patent_app_date] => 2019-03-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 28946 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -9 [patent_words_short_claim] => 84 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16501210 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17368343 [patent_doc_number] => 20220023395 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-01-27 [patent_title] => METHODS OF TREATING OR PREVENTING CANCER WITH AN AGENT THAT DEPLETES TREGS AND A CHECKPOINT INHIBITOR [patent_app_type] => utility [patent_app_number] => 16/978949 [patent_app_country] => US [patent_app_date] => 2019-03-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 26730 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -9 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16978949 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16727848 [patent_doc_number] => 20210094995 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-04-01 [patent_title] => METHODS AND COMPOSITIONS FOR TREATING CANCER WITH ECM-AFFINITY PEPTIDES LINKED TO CYTOKINES [patent_app_type] => utility [patent_app_number] => 15/733582 [patent_app_country] => US [patent_app_date] => 2019-03-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 28257 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -44 [patent_words_short_claim] => 29 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15733582 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17407164 [patent_doc_number] => 11248033 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2022-02-15 [patent_title] => Methods and compositions for treating cancer [patent_app_type] => utility [patent_app_number] => 16/281472 [patent_app_country] => US [patent_app_date] => 2019-02-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 17 [patent_figures_cnt] => 20 [patent_no_of_words] => 20008 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 17 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16281472 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20373518 [patent_doc_number] => 12480950 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-11-25 [patent_title] => AKT-specific capture agents, compositions, and methods of using and making [patent_app_type] => utility [patent_app_number] => 16/280953 [patent_app_country] => US [patent_app_date] => 2019-02-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 50 [patent_figures_cnt] => 66 [patent_no_of_words] => 20587 [patent_no_of_claims] => 35 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 126 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16280953 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14685055 [patent_doc_number] => 20190241642 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-08-08 [patent_title] => SYSTEM AND METHOD FOR HOMOGENOUS GPCR PHOSPHORYLATION AND IDENTIFICATION OF BETA-2 ADRENERGIC RECEPTOR POSITIVE ALLOSTERIC MODULATORS [patent_app_type] => utility [patent_app_number] => 16/269877 [patent_app_country] => US [patent_app_date] => 2019-02-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 30534 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16269877 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14838887 [patent_doc_number] => 20190277844 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-09-12 [patent_title] => DISRUPTION OF EGFR-SAR1 INTERACTION FOR CANCER TREATMENT [patent_app_type] => utility [patent_app_number] => 16/254287 [patent_app_country] => US [patent_app_date] => 2019-01-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 15942 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 20 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16254287 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14581357 [patent_doc_number] => 20190218287 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-07-18 [patent_title] => TRPM4 CHANNEL INHIBITORS FOR STROKE TREATMENT [patent_app_type] => utility [patent_app_number] => 16/249706 [patent_app_country] => US [patent_app_date] => 2019-01-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 13258 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -8 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16249706 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14535133 [patent_doc_number] => 20190203188 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-07-04 [patent_title] => FUSION PROTEINS AND METHODS THEREOF [patent_app_type] => utility [patent_app_number] => 16/246167 [patent_app_country] => US [patent_app_date] => 2019-01-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 41796 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -7 [patent_words_short_claim] => 30 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16246167 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14778067 [patent_doc_number] => 20190263931 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-08-29 [patent_title] => ANTI-MCT1 ANTIBODIES AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 16/240499 [patent_app_country] => US [patent_app_date] => 2019-01-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 67605 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -24 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16240499 [rel_patent_id] =>[rel_patent_doc_number] =>)